SF 3591 would tighten Minnesota’s cannabis and hemp product rules by setting explicit THC potency caps for several product categories and by restricting certain product forms from the adult-use market. The bill directs the Office to enforce maximum total THC levels of 15 percent for cannabis flower, 30 percent for cannabis concentrate, and 500 milligrams per package for topical or transdermal cannabis and hemp products. It also bars the Office from approving cannabis flower or prerolls infused with additional THC or other psychoactive cannabinoids, and it prohibits products that resemble candy, desserts, fruit, children’s brands, meat or dairy products, or that contain synthetic cannabinoids or non-FDA-approved food ingredients in edibles.
The bill also expands retail warning requirements and product labeling rules for cannabis and hemp businesses. Retail locations would have to post multiple health and safety warnings about impaired driving, age restrictions, smoking risks, psychosis, delayed onset of edibles, THC potency, and topical use. Packaging labels would need more detailed information, including source and manufacturer information, batch numbers, cannabinoid profiles, testing verification, usage instructions, universal symbols, poison-control information, and several standardized warning statements about child safety, brain development, mental health, dependence, pregnancy, and driving impairment. The bill also defines “preroll” and references “substance use disorder” for purposes of the cannabis code.
In terms of state law, the bill amends Minnesota Statutes sections 342.01, 342.06, 342.27, and 342.63, all within the state’s cannabis regulatory framework. Its practical effect would be to give the Office clearer authority to police product potency, packaging, and marketing, while imposing more detailed compliance obligations on cannabis businesses, hemp businesses, manufacturers, and growers. It would likely affect adult-use cannabis retailers, hemp-derived consumer product sellers, and producers of concentrates, edibles, topicals, and transdermal products.
Because there are no committee transcripts or recorded votes provided, the overall sentiment cannot be measured from debate or roll call history. Based on the bill text alone, the measure appears to reflect a public-health and consumer-protection approach, emphasizing youth protection, poison prevention, and limits on high-potency or appealing-to-children products. The bill’s tone suggests support for stricter regulation rather than market expansion.
The main points of contention likely involve the potency caps, the ban on infused flower and prerolls, and the broad restrictions on product appearance and ingredients. Cannabis businesses and hemp product manufacturers may view these provisions as limiting product innovation and market options, while public-health advocates are likely to support the warning-label expansion and child-appeal restrictions. The bill also creates compliance burdens through detailed labeling and posting requirements, which could be a concern for smaller operators.
SF 3591 would amend Minnesota’s cannabis statutes to impose mandatory THC potency limits, restrict certain product types and formulations, and expand labeling and retail warning requirements. It would directly affect cannabis businesses, hemp businesses, growers, manufacturers, and retailers by requiring new product approvals, packaging disclosures, and point-of-sale notices, while giving the Office stronger enforcement authority over adult-use cannabis and hemp-derived consumer products.
No committee testimony or voting record is provided, so there is no direct evidence of legislative support or opposition from the available history. The bill’s text indicates a generally cautious, health-focused approach, with an emphasis on consumer warnings, child safety, and limits on high-potency products, suggesting likely support from regulators and public-health advocates and likely concern from industry stakeholders.
Likely areas of disagreement include the proposed THC caps for flower, concentrates, and topicals; the prohibition on infused flower and infused prerolls; and the ban on products that resemble candy, desserts, fruit, or child-marketed brands. Industry stakeholders may object to the operational and labeling burdens, while supporters may argue the bill is necessary to reduce youth appeal, poisoning risks, and adverse health effects. The bill also appears to draw a line against synthetic cannabinoids and non-FDA-approved edible ingredients, which could be another point of dispute for hemp and cannabis product manufacturers.